Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Feb 28;14(2):323-327.
doi: 10.21037/tlcr-24-854. Epub 2025 Feb 18.

Will "Sun"-WUKONG, the monkey king, conquer EGFR exon 20 insertion mutation positive non-small cell lung cancer?

Molly Li  1 , Ross A Soo  2
Affiliations
Editorial

Will "Sun"-WUKONG, the monkey king, conquer EGFR exon 20 insertion mutation positive non-small cell lung cancer?

Molly Li et al. Transl Lung Cancer Res. .
No abstract available

Keywords: EGFR exon 20 insertion mutations; EGFR tyrosine kinase inhibitors; sunvozertinib; uncommon EGFR mutations.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-854/coif). M.L. reports research funding from AstraZeneca, Gilead, MSD, Takeda, and Johnson & Johnson; honoraria from AstraZeneca, Novartis, Amgen, Pfizer, Takeda, ACE Oncology, Gilead, Guardant Health, Johnson & Johnson, Merck, MSD and BMS; support for attending meetings from AstraZeneca, Pfizer, Daiichi Sankyo, MSD, Roche, Johnson & Johnson, and Amgen; and has participation on advisory board of AstraZeneca, Pfizer, Takeda, Amgen, AnHeart Therapeutics, Yuhan, Blossomhill Therapeutics, and Johnson & Johnson. R.A.S. reports receiving research funding from AstraZeneca, Boehringer Ingelheim, Pfizer; honoraria for lectures, presentations from Abbvie, Amgen, AnHeart, Astra-Zeneca, Bayer, BMS, Boehringer Ingelheim, Chugai, Daiichi Sankyo, GSK, J INTS BIO, Janssen, Lily, Merck, Merck Serono, Novartis, Pfizer, Puma, Roche, Sanofi, Taiho, Takeda, Thermo Fisher, Yuhan Corporation and has participation on Advisory Board of Abbvie, Amgen, AnHeart, Astra-Zeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, GSK, J INTS BIO, Janssen, Lily, Merck, Merck Serono, Novartis, Pfizer, Puma, Roche, Sanofi, Taiho, Takeda, Thermo Fisher, Yuhan Corporation. The authors have no other conflicts of interest to declare.

Comment on

References

    1. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500. 10.1126/science.1099314 - DOI - PubMed
    1. Low JL, Lim SM, Lee JB, et al. Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations. Ther Adv Med Oncol 2023;15:17588359221146131. 10.1177/17588359221146131 - DOI - PMC - PubMed
    1. Carey KD, Garton AJ, Romero MS, et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 2006;66:8163-71. 10.1158/0008-5472.CAN-06-0453 - DOI - PubMed
    1. Yasuda H, Park E, Yun CH, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 2013;5:216ra177. 10.1126/scitranslmed.3007205 - DOI - PMC - PubMed
    1. Bazhenova L, Minchom A, Viteri S, et al. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer 2021;162:154-61. 10.1016/j.lungcan.2021.10.020 - DOI - PubMed

LinkOut - more resources